Skip to main content Skip to section navigation Skip to footer
Kazia Therapeutics Corporate homepage
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Pipeline
    • Pipeline Overview
    • Paxalisib
    • PD-L1 Protein Degrader
    • SETDB1 Inhibitor
    • EVT801
    • Clinical Trials
    • Posters & Publications
  • Technology
  • Media Center
    • Media Center Overview
    • News
    • Events
    • In The News
    • Video Gallery
    • ASX Announcements
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
    • ASX Delisting
  • Contact Us

ASX Announcements

Media Center

  • Media Center Overview
  • News
  • Events
  • In The News
  • Video Gallery
  • ASX Announcements
Oct 31, 2022
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 28, 2022
Change in substantial holding
Oct 27, 2022
Positive melanoma data for Kazia's paxalisib
Oct 18, 2022
Kazia SEC Form 20F
Oct 14, 2022
Notice of Annual General Meeting/Proxy Form
Oct 13, 2022
Application for quotation of securities - KZA
Oct 13, 2022
Cleansing notice
Oct 6, 2022
Expansion of PNOC study into Australia
Sep 26, 2022
Kazia AGM date
Sep 21, 2022
Application for quotation of securities - KZA
rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • …
  • Page 19
  • Next Pagearrow_forward
©2026 Kazia Therapeutics. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement